Observational studyFundamental & clinical pharmacology2026
Association of Acute Kidney Injury and Chronic Kidney Disease With Concentration-To-Dose Ratios of Midazolam and Its Main Metabolites in Critically Ill Adults.
Observational study in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMidazolam (MDZ) is used for sedation in critically ill patients. Although previous studies have examined MDZ pharmacokinetics in ICU patients, the differential effects of acute kidney injury (AKI) and chronic kidney disease (CKD), particularly in cohorts including COVID-19 and non-COVID-19 patients, remain insufficiently characterised.
objectivesTo investigate whether AKI and CKD are associated with dose-normalised exposure of MDZ, 1-hydroxy-midazolam (1-OH-MDZ) and 1-hydroxy-midazolam glucuronide (1-OH-MDZ-G) in critically ill adults.
methodsIn this retrospective observational study, ICU patients receiving continuous intravenous MDZ were included. Plasma concentrations of MDZ, 1-OH-MDZ and 1-OH-MDZ-G were converted to concentration-to-dose (C/D) ratios. Cross-sectional analysis used the first sample per patient; longitudinal analysis included all samples in GEE models. Analyses were adjusted for age, sex, BMI, COVID-19 status, CYP3A4 inhibitor use, APACHE IV score, time since MDZ initiation and CRP.
resultsForty-seven patients contributed 137 samples. In the cross-sectional analysis, C/D ratios of MDZ and 1-OH-MDZ did not differ between patients with and without AKI, whereas 1-OH-MDZ-G C/D ratios were higher in AKI (median [IQR] 14.54 [6.14-26.20] vs. 4.53 [2.52-6.00]; p < 0.01). Longitudinal analysis showed that AKI (β = 0.87), AKI Stage 1 (β = 0.81), AKI Stages 2-3 (β = 0.97) and CKD (β = 0.72) were all significantly associated with higher 1-OH-MDZ-G C/D ratios (all p ≤ 0.03). No significant associations were observed for MDZ or 1-OH-MDZ.
conclusionAKI and CKD are associated with accumulation of 1-OH-MDZ-G in critically ill patients. Monitoring 1-OH-MDZ-G may help identify patients at risk of prolonged sedation and adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.